TCM Biotech International (ROCO:4169) Long-Term Capital Lease Obligation : NT$4.8 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is TCM Biotech International Long-Term Capital Lease Obligation?

TCM Biotech International's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$4.8 Mil.

TCM Biotech International's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (NT$6.5 Mil) to Jun. 2023 (NT$5.3 Mil) and declined from Jun. 2023 (NT$5.3 Mil) to Dec. 2023 (NT$4.8 Mil).

TCM Biotech International's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (NT$1.5 Mil) to Dec. 2022 (NT$6.5 Mil) but then declined from Dec. 2022 (NT$6.5 Mil) to Dec. 2023 (NT$4.8 Mil).

TCM Biotech International Long-Term Capital Lease Obligation Historical Data

The historical data trend for TCM Biotech International's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCM Biotech International Long-Term Capital Lease Obligation Chart

TCM Biotech International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.73

3.29

1.45

6.49

4.81

TCM Biotech International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.45	1.57	6.49	5.29	4.81

TCM Biotech International (ROCO:4169) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

TCM Biotech International Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of TCM Biotech International's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

TCM Biotech International (ROCO:4169) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCM Biotech International Corp (ROCO:4169) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 97, Sec. 1, Xintai 5th Road, Xizhi District, Neihu District, Taipei, TWN, 221

Website

http://www.tcmbio.com

TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.

TCM Biotech International (ROCO:4169) Headlines

No Headlines